|
Integrin Targeted Therapy for the Treatment of Ovarian Cancer
|
1R41CA168228-01A1
|
$299,849
|
$299,849
|
Calzone, Frank
|
APPLIED INTEGRIN SCIENCES, INC.
|
|
Understanding the origin and pathogenesis of epithelial ovarian cancer
|
5F32CA159523-02
|
$55,670
|
$55,670
|
Kim, Jaeyeon
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-06S1
|
$41,433
|
$829
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-06S2
|
$75,000
|
$1,500
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-06
|
$2,934,758
|
$58,695
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Role of the BMP SMADs in Oncogenesis
|
5R01CA138628-03
|
$354,370
|
$354,370
|
Pangas, Stephanie
|
BAYLOR COLLEGE OF MEDICINE
|
|
Virginia Mason Community Clinical Oncology Program
|
5U10CA035192-28
|
$607,994
|
$42,560
|
Nichols, Craig
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
Analysis of BRCA1 recombination functions
|
5R01CA095175-09
|
$295,223
|
$147,612
|
SCULLY, RALPH
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Rectifying defects in tumor vasculature to improve chemo- and radiation therapies
|
5R01CA129339-05
|
$342,168
|
$85,542
|
SENGER, DONALD
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Utrasensitive bioassays using palladium catalyzed chemical amplification
|
5R43CA159478-02
|
$100,578
|
$75,434
|
Lelental, Mark
|
BIOFORMATIX, INC.
|
|
A Novel Nanocoaxial Biosensor for Detection of Cancer Biomarkers
|
5R21CA137681-03
|
$231,123
|
$231,123
|
CHILES, THOMAS
|
BOSTON COLLEGE
|
|
Women's Health Study: Continued Follow-up
|
5R01CA047988-21
|
$1,813,397
|
$362,679
|
BURING, JULIE
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Screening and Risk Biomarkers for Ovarian Cancer in EPIC Specimens
|
1R01CA158119-01A1
|
$566,874
|
$566,874
|
CRAMER, DANIEL
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Multifunctional nanoparticles for targeting aberrant tumorigenic pathways
|
5R01CA135242-03
|
$359,276
|
$118,561
|
Sengupta, Shiladitya
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Dietary and Hormonal Determinants of Cancer in Women
|
5P01CA087969-13
|
$4,908,989
|
$1,178,157
|
Stampfer, Meir
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Psychological stress, associate biologic mediators, and ovarian cancer risk
|
1R01CA163451-01A1
|
$469,872
|
$469,872
|
Tworoger, Shelley
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Characteristics of tubal ligation and risk of epithelial ovarian cancer
|
5R03CA143918-02
|
$96,177
|
$96,177
|
Tworoger, Shelley
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Proteo-genomic Discovery, Prioritization and Verification of Cancer Biomarkers
|
5U24CA160034-02
|
$3,122,514
|
$780,629
|
CARR, STEVEN
|
BROAD INSTITUTE, INC.
|
|
Nanosystems Biology Cancer Center 2
|
5U54CA151819-03
|
$2,463,138
|
$394,102
|
HEATH, JAMES
|
CALIFORNIA INSTITUTE OF TECHNOLOGY
|
|
Carle Cancer Center Community Clinical Oncology Program
|
5U10CA035195-29
|
$728,213
|
$65,539
|
ROWLAND, KENDRITH
|
CARLE FOUNDATION
|
|
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis
|
5U01CA062502-19
|
$594,035
|
$5,940
|
DOWLATI, AFSHIN
|
CASE WESTERN RESERVE UNIVERSITY
|
|
A NOVEL MICROFLUIDIC DEVICE FOR SELECTION AND OPTIMIZATION OF DRUG DELIVERY VEHIC
|
2R44CA139841-02A1
|
$633,309
|
$158,327
|
PRABHAKARPANDIAN, BALABHASKAR
|
CFD RESEARCH CORPORATION
|
|
Cytogenetic and Molecular Studies of Chromosome 22
|
5R01CA039926-24
|
$366,215
|
$91,554
|
EMANUEL, BEVERLY
|
CHILDRENS HOSPITAL OF PHILADELPHIA
|
|
Delaware/Christiana Care Community Clinical Oncology Program
|
2U10CA045418-26
|
$1,423,934
|
$56,957
|
GRUBBS, STEPHEN
|
CHRISTIANA CARE HEALTH SERVICES, INC.
|
|
Research and Mentoring on Energetic Factors and Cancer: Established Investigator
|
5K05CA136967-04
|
$137,885
|
$6,894
|
BERNSTEIN, LESLIE
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Breast and Other Cancers in the California Teachers Cohort
|
5R01CA077398-14
|
$2,522,927
|
$252,293
|
BERNSTEIN, LESLIE
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA033572-29S1
|
$91,911
|
$919
|
FRIEDMAN, MICHAEL
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA033572-29S2
|
$139,999
|
$1,400
|
FRIEDMAN, MICHAEL
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA033572-29S3
|
$75,000
|
$750
|
FRIEDMAN, MICHAEL
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
5P30CA033572-29
|
$2,225,352
|
$22,254
|
FRIEDMAN, MICHAEL
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
COMPUTATIONAL AND FUNCTIONAL APPROACHES TO VALIDATING CANCER GENOME TARGETS
|
1U01CA168409-01
|
$1,405,573
|
$351,393
|
POWERS, SCOTT
|
COLD SPRING HARBOR LABORATORY
|
|
CSHL CANCER CENTER SUPPORT GRANT
|
5P30CA045508-25
|
$4,346,720
|
$173,869
|
STILLMAN, BRUCE
|
COLD SPRING HARBOR LABORATORY
|
|
CCOP: Colorado Cancer Research Program
|
2U10CA067753-17
|
$1,128,806
|
$124,169
|
PAJON, EDUARDO
|
COLORADO CANCER RESEARCH PROGRAM, INC.
|
|
Integrative Cancer Genomics: Drivers, Pathways and Drugs
|
1R01CA164729-01A1
|
$399,632
|
$59,945
|
Pe'er, Dana
|
COLUMBIA UNIV NEW YORK MORNINGSIDE
|
|
Cancer Center Support Grant
|
2P30CA006516-47
|
$11,164,583
|
$446,583
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA006516-47S1
|
$56,572
|
$2,263
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA006516-47S2
|
$75,000
|
$3,000
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA006516-47S3
|
$50,000
|
$2,000
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
The High Cost of Risk Reduction: Addressing Sexual Dysfunction after Oophorectomy
|
5R03CA153815-02
|
$87,500
|
$87,500
|
Bober, Sharon
|
DANA-FARBER CANCER INSTITUTE
|
|
Investigate role of microRNA cluster 183-96-182 in DNA repair and radiosensitivit
|
5R01CA142698-03
|
$352,231
|
$176,116
|
Chowdhury, Dipanjan
|
DANA-FARBER CANCER INSTITUTE
|
|
Functional Annotation of Cancer Genomes: TCGA, Glioblastoma and Ovarian Cancer
|
3RC2CA148268-02S1
|
$639,047
|
$319,524
|
HAHN, WILLIAM
|
DANA-FARBER CANCER INSTITUTE
|
|
BRCA1 Function in Post-Damage Nuclear Foci
|
5R01CA136512-04
|
$511,599
|
$127,900
|
LIVINGSTON, DAVID
|
DANA-FARBER CANCER INSTITUTE
|
|
Dartmouth Center for Cancer Nanotechnology Excellence
|
5U54CA151662-03
|
$2,353,780
|
$776,747
|
Baker, Ian
|
DARTMOUTH COLLEGE
|
|
Cancer Center Support Grant
|
3P30CA023108-34S1
|
$74,921
|
$2,248
|
ISRAEL, MARK
|
DARTMOUTH COLLEGE
|
|
Cancer Center Support Grant
|
3P30CA023108-34S2
|
$49,921
|
$1,498
|
ISRAEL, MARK
|
DARTMOUTH COLLEGE
|
|
Cancer Center Support Grant
|
5P30CA023108-34
|
$3,125,750
|
$93,773
|
ISRAEL, MARK
|
DARTMOUTH COLLEGE
|
|
Chimeric NKG2D receptors in ovarian cancer immunotherapy
|
5R01CA130911-05
|
$321,839
|
$321,839
|
SENTMAN, CHARLES
|
DARTMOUTH COLLEGE
|
|
CENTRAL ILLINOIS COMMUNITY CLINICAL ONCOLOGY PROGRAM
|
5U10CA045807-27
|
$1,361,380
|
$108,910
|
WADE, JAMES
|
DECATUR MEMORIAL HOSPITAL
|
|
Role of TbRIII in Regulating Motility and Invasion
|
5R01CA135006-04
|
$423,323
|
$211,662
|
BLOBE, GERARD
|
DUKE UNIVERSITY
|
|
Adherence to Cancer Risk Management Among Unaffected BRCA1/2Mutation Carriers
|
5R03CA157212-02
|
$84,884
|
$42,442
|
Buchanan, Adam
|
DUKE UNIVERSITY
|
Total relevant funding to Ovarian Cancer for this search: $111,657,265
|